Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome.
Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome.
ionis pharmaceuticals股價上漲，公司公佈Q3財務業績超出預期，並宣佈與FDA就ION582用於安吉曼綜合症的關鍵第3階段研究設計達成一致。
Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome.
ionis pharmaceuticals股價上漲，公司公佈Q3財務業績超出預期，並宣佈與FDA就ION582用於安吉曼綜合症的關鍵第3階段研究設計達成一致。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間